Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, Katrina Z. Kao, Ana Lako, Junko Tsuji, Yang Liu, Ryan C. Brennick, Ryan D. Gentzler, Carrie Lee, Joleen Hubbard, Susanne M. Arnold, James L. Abbruzzese, Salma K. Jabbour, Nataliya V. Uboha, Kevin L. Stephans, Jennifer M. Johnson, Haeseong Park, Liza C. Villaruz, Elad SharonHoward Streicher, Mansoor M. Ahmed, Hayley Lyon, Carrie Cibuskis, Niall Lennon, Aashna Jhaveri, Lin Yang, Jennifer Altreuter, Lauren Gunasti, Jason L. Weirather, Raymond H. Mak, Mark M. Awad, Scott J. Rodig, Helen X. Chen, Catherine J. Wu, Arta M. Monjazeb, F. Stephen Hodi

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences